A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7834-7840

  Boddy, Alan V ^a   Plummer, E Ruth ^a,b   Todd, Radha ^b   Sludden, Julieann ^a   Griffin, Melanie ^a   Robson, Lesley ^c   Cassidy, James ^d   Bissett, Donald ^d   Bernareggi, Alberto ^e   Verrill, Mark W ^a,b   Calvert, A Hilary ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Northern Centre for Cancer Treatment   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e Cell Therapeutics Inc (Europe)   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PACLITAXEL POLIGLUMEX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CARCINOMA; STOMATITIS; TOXICITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, CHEMICAL; NEOPLASMS; PACLITAXEL; POLYGLUTAMIC ACID; POLYMERS; TIME FACTORS;

EID: 27744553029     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0803     Document Type: Article

References (26)

1. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003;22:9075-86.
2. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353-74.
3. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug forumulation. Eur J Cancer 2001;37:1590-8.
4. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44.
5. Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-16.
6. Soepenberg O, Sparreboom A, de Jonge MJA, et al. Real-time pharmacokinetics guiding clinical decisions: phase I study of a weekly schedule of liposome with solid encapsulated paclitaxel in patients tumours. Eur J Cancer 2004;40:681-8.
7. Rose WC, Clark JL, Lee FYF, Casazza AM. Preclinical antitumour activity of water-soluble paclitaxel derivatives. Cancer Chemother Pharmacol 1997;39:486-92.
8. Rowinsky EK. Taxane analogues: Distinguishing royal robes from the "Emperor's New Clothes." Clin Cancer Res 2002;8:2759-63.
9. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60.
10. Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 2003;42:1089-105.
11. Matsumura Y, Maeda H. A new concept for macro-molecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92.
12. Jensen KD, Nori A, Tijerina M, Kopeckova P, Kopecek J. Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J Control Release 2003;87:89-105.
13. Li C, Price JE, Milas L, et al. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res 1999;5:891-7.
14. Li C, Newman RA, Wu Q-P, et al. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol 2000;46:416-22.
15. Singer JW, Baker B, de Vries P, et al. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAXTM], a biodegradable polymeric drug conjugate. In: Maeda H, editor, translator and editor. Polymer drugs in the clinical stage. New York: Kluwer Academic/Plenum Publishers; 2003. p. 81-90.
16. Siddiqui N, Boddy AV, Thomas HD, et al. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br J Cancer 1997;75;287-94.
17. Boddy AV, Griffin MJ, Sludden J, et al. Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. Cancer Chemother Pharmacol 2001;48:15-21.
18. Buzdar AU, Holmes FA, Hortobagyi GN. Paclitaxel in the treatment of metastatic breast cancer-MD Anderson Cancer Center experience. Semin Oncol 1995;22:101 -4.
19. Greco FA, Hainsworth JD. Phase I/II trial comparing 1-hour infusion schedules. Semin Oncol 1994;21:3-8.
20. Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994;12:241-8.
21. Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-26. J Clin Oncol 1999;17:3403-11.
22. Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 2000;23:401-28.
23. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342. J Clin Oncol 2004;22:2061-8.
24. Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998;16:153-8.
25. Kunitoh H, Saijo N, Furuse K, Noda K, Ogawa M. Neuromuscular toxicities of paclitaxel 210 mg.m-2 by 3-hour infusion. Br J Cancer 1998;77:1686-8.
26. Sabbatini P, Aghajanian C, Dizon D, et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 2004;22:4523-31.